Efficacy and safety of a 14‐day modified concomitant therapy for refractory Helicobacter pylori infection: a pilot study
Journal of Gastroenterology and Hepatology · 2023
DOI: 10.1111/jgh.16348 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, 2023. Verfasst von Shu-Yan Zeng und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan, Shandong, China. Hauptthemen laut MEDLINE: Helicobacter Infections, Helicobacter pylori. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Taishan Scholars Program of Shandong Province.
Abstract (Originalsprache)
Background and Aim After three treatment failures, Helicobacter pylori infection is deemed refractory as antibiotic treatment options become significantly limited. This study evaluated the efficacy and safety of a 14‐day modified concomitant therapy for managing refractory H. pylori infection.
Methods
Patients who had failed to respond to three or more rounds of H. pylori therapies were recruited for this study. They received a 14‐day modified concomitant therapy, including esomeprazole 40 mg, amoxicillin 1000 mg, and furazolidone 100 mg twice daily and tetracycline 500 mg four times daily. Demographic data, adverse events, and patient compliance were recorded. The presence of H. pylori was reevaluated 6 weeks following treatment. Eradication rate was assessed as the primary outcome.
Results
Overall, 59 participants received the 14‐day modified concomitant therapy. In the intention‐to‐treat and per‐protocol analyses, the eradication rate was 84.7% (50/59) and 89.3% (50/56), respectively. H. pylori was successfully isolated from 75.0% (12/16) of patients. The resistance rate of H. pylori to metronidazole, levofloxacin, and clarithromycin was 91.7% (11/12), 58.3% (7/12), and 50.0% (6/12), respectively. Resistance to amoxicillin, furazolidone, or tetracycline was not observed. The frequency of adverse events was 35.6% (21/59), with no serious adverse events reported.
Conclusion
The 14‐day modified concomitant therapy appears to be appropriate for refractory H. pylori infection and is particularly promising for the Chinese population. A randomized controlled trial is warranted to verify its efficacy, especially in the current environment of increasing antibiotic resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan, Shandong, China.
- Laboratory of Translational Gastroenterology, Qilu Hospital of Shandong University, Jinan, Shandong, China.
- Hospital Development Center of Qingdao Municipal Health Commission, Qingdao, Shandong, China.
ORCID-Profile: Yue-Yue Li, Xiu-Li Zuo, Yan-Qing Li
Förderung
- National Natural Science Foundation of China
- Taishan Scholars Program of Shandong Province
Zitieren
APA
Zeng, S. Y., Wang, J., Liu, J., Lin, M. J., Lin, B. S., Ding, Y. M., Kong, Q. Z., Zhang, W. L., Duan, M., Han, Z. X., Li, Y. Y., Zuo, X. L., & Li, Y. Q. (2023). Efficacy and safety of a 14‐day modified concomitant therapy for refractory Helicobacter pylori infection: a pilot study. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16348
Vancouver
Zeng SY, Wang J, Liu J, Lin MJ, Lin BS, Ding YM, et al. Efficacy and safety of a 14‐day modified concomitant therapy for refractory Helicobacter pylori infection: a pilot study. Journal of Gastroenterology and Hepatology. 2023. doi:10.1111/jgh.16348
BibTeX
@article{Zeng2023,
author = {Zeng, Shu-Yan and Wang, Juan and Liu, Jing and Lin, Min-Juan and Lin, Bo-Shen and Ding, Yu-Ming and Kong, Qing-Zhou and Zhang, Wen-Lin and Duan, Miao and Han, Zhong-Xue and Li, Yue-Yue and Zuo, Xiu-Li and Li, Yan-Qing},
title = {Efficacy and safety of a 14‐day modified concomitant therapy for refractory Helicobacter pylori infection: a pilot study},
journal = {Journal of Gastroenterology and Hepatology},
year = {2023},
doi = {10.1111/jgh.16348}
}
EUVIMED